The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia.

Xospata (gilteritinib) - Astellas

Vanflyta (quizartinib) - Daiichi Sankyo

http://www.ncbi.nlm.nih.gov/pubmed/42696088

Fangfang Yang; Jiajun He; Jiaqi Fan; Peihong Wang; Qi Xiang; Shiyang Wang; Shunqing Wang; Yuping Zhang; Yvyin Zhang; Zhiwei Zhong

Sep 5, 2026